PMOS Treatment Pipeline Remains Limited, Experts Say
New drugs are being studied as PMOS research expands worldwide
Key Developments:
- PMOS replaces the former PCOS terminology
- Metformin and contraceptives remain established options
- New drugs are being tested, but evidence remains limited
(LABIOTECH) — September 29, 2026: The treatment landscape for polyendocrine metabolic ovarian syndrome (PMOS), formerly known as polycystic ovary syndrome (PCOS), remains limited as researchers investigate therapies targeting its hormonal, metabolic and reproductive effects.
PMOS affects an estimated one in eight women globally, or more than 170 million people, according to the Endocrine Society. The condition can involve reproductive, metabolic, psychological and dermatological features, while its underlying causes are considered complex rather than attributable to a single factor.
Up to 20m Pakistani Women May Have PMOS: Experts
The international medical community adopted PMOS as the new name for the condition in an effort to better reflect its broader effects beyond the ovaries. The international evidence-based guideline notes that the evidence supporting PMOS management has improved but remains generally low to moderate in quality, highlighting the need for further research.
“PMOS is a chronic endocrine disorder with a lifelong impact,” said Sanj Singh, chief executive of women's health company Temple Therapeutics, according to LABiotech.
Photo Credits: Kindel Media (Pexels).
Existing treatment generally focuses on managing individual symptoms and health risks rather than addressing a single established underlying cause. International guidance supports lifestyle management for metabolic health, while medicines such as combined oral contraceptives and metformin can be considered for specific symptoms or metabolic features. Fertility treatment can involve medicines such as letrozole when ovulation-related infertility is present.
Researchers are also investigating whether medicines already used for other conditions could have a role in PMOS. LABiotech reports that studies have examined combinations involving metformin and the diabetes drug dapagliflozin, although findings have been mixed and further research is required.
Mian Amjad Farzand Re-Elected Chairman of Pakistan Film Producers Association for Third Term
Lata Mangeshkar Birth Anniversary: Remembering the Nightingale on Her Special Day
Three Traffic Police Personnel Martyred in Armed Attack in Tank
Another area of interest is the use of GLP-1-based medicines, particularly for patients with overweight or obesity and associated metabolic problems. LABiotech reports that studies have found improvements in some metabolic and menstrual outcomes, but also notes side effects and differences in results according to the degree of obesity.
Shanghai-based Hengrui Pharma's ribupatide is among the newer candidates highlighted in the report. According to LABiotech, Phase 2 studies showed substantial weight loss and some improvement in menstrual regularity among participants with PMOS. However, these findings remain investigational and should not be interpreted as evidence that the drug is an approved PMOS treatment.
Temple Therapeutics is also exploring TTX-336, an androgen receptor modulator that the company's CEO described as a potential disease-modifying approach. “Should TTX-336 be approved, it will hit the key endpoints desired by patients,” Singh said, according to LABiotech. The therapy remains under development and is not an established treatment.
CREDIT: AI-generated image via Chat GPT.
Researchers are additionally examining inositol and repurposed medicines as possible approaches. Some studies have reported improvements in metabolic or reproductive measures, but the international guideline stresses the need for stronger evidence before many emerging approaches can be considered established PMOS therapies.
What Eating Two Eggs Daily May Mean for Health
Three Traffic Police Personnel Martyred in Armed Attack in Tank
Sialkot Airport Denies Misleading Reports Qatar Airways Flight Landed in Pakistan, Not India
The broader treatment challenge is that PMOS can present differently from one patient to another, involving menstrual irregularities, excess androgen activity, metabolic problems, fertility difficulties and psychological symptoms. As a result, current international guidance emphasizes individualized care and shared decision-making rather than a single treatment for all patients.
The shift from PCOS to PMOS is therefore accompanied by a broader effort to improve diagnosis, treatment and research. While several potential therapies are moving through clinical investigation, patients and healthcare professionals continue to rely largely on established symptom- and risk-based management while researchers work toward more targeted treatments.
IIOJK Assembly Passes Omar Abdullah's Statehood Resolution Amid BJP Walkout
AI Actress Tilly Norwood Still Has No Agent
US Ambassador Sergio Gor Pays Obeisance at Golden Temple During Amritsar Visit
Major Shuffle in Military Intelligence
Thousands of Muslims Occupy Historic Shahi Mosque in Ujjain to Halt Partial Demolition
Stay tuned to Baaghi TV for more. Download our app for the latest news, updates & uncensored content!
Doctors Urge Early PMOS Diagnosis for Fertility Care
Specialists highlight the link between ovulation, PMOS and fertility planning
Up to 20m Pakistani Women May Have PMOS: Experts
Experts urge early diagnosis as PMOS concerns grow among Pakistani women
Further Reads
